Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
US8293800B2 · kind B2 · utility
2Cited by
0References
12Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 28, 2010 |
| Grant date | Oct 23, 2012 |
| Priority date | — |
| Expiry date | Apr 28, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.